---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-024583"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2026-04-10T23:59:59+00:00"
generated_at: "2026-05-15T06:40:59.576520+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics amends bylaws to designate exclusive forum for federal securities claims

## Summary
- Board approved by-laws amendment effective April 9, 2026 designating U.S. District Courts for Massachusetts and Delaware as exclusive forums for Securities Act and Exchange Act claims.
- Amendment responds to recent changes in Delaware General Corporation Law regarding forum selection provisions.
- Company may consent in writing to an alternative forum; full text filed as Exhibit 3.1.
- No financial impact; governance change only.

## SEC filing metadata
- accession: 0001628280-26-024583
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2026-04-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828026024583/0001628280-26-024583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828026024583/cccc-20260410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-024583
- JSON: https://secwatch.observer/filing/0001628280-26-024583.json
- Plain text: https://secwatch.observer/filing/0001628280-26-024583.txt

## Source-grounded claims
- claim_id: 6be12d578600df20c8e6ccbad60365dc98c50568
  claim: C4 Therapeutics, Inc.: Amended bylaws to designate exclusive federal forum for Securities Act and Exchange Act claims, effective immediately (effective 2026-04-09).
  evidence_excerpt: On April 9, 2026, the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s second amended and restated by-laws (the “By-laws Amendment”), effective immediately, to designate the United States District Court for the District of Massachusetts and the United States District Court for the District of Delaware as the exclusive forums for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828026024583/0001628280-26-024583-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.